Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Dermatology | Immunology | Rheumatology | Family Medicine
Search Medical Condition
Psoriatic Arthritis Clinical Trials
A listing of Psoriatic Arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (72) clinical trials
Psoriatic Arthritis
Local doctors are looking for people with Psoriatic Arthritis (PsA) for clinical research studies of an investigational medication. Compensation provided for time and travel!
Psoriatic Arthritis – Inadequate response to biologic DMARDs
A research study is evaluating an investigational medication for psoriatic arthritis This research study may be an option if you: Are at least 18 years of age Have a diagnosis of active psoriatic arthritis for at least 6 months Have a history of or current plaque psoriasis Have at least ...
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis
This study of Etanercept and Methotrexate compared to Etanercept alone and Methotrexate alone will last up to 52 weeks. Qualified participants may receive compensation for study-related travel.
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3.5-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor ...
PSA-006
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects with Active Psoriatic Arthritis
Psoriatic Arthritis Research Study
Study Description: Local doctors are looking for people with Psoriatic Arthritis for clinical research studies of an investigational medication. Eligibility criteria (inclusion and exclusion): Must be receiving treatment for Psoriatic Arthritis Must be at least 18 years old Psoriatic Arthritis must be present for at least 3 months prior to ...
A 52 week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler Ultrasonography in patients with active psoriatic arthritis (PsA)
Study of the application of Power Doppler Ultrasonography (PDUS) to measure response to secukinumab treatment in patients with active psoriatic arthritis (PsA)
Phase 3b Study comparing secukinumab (Cosentyx) versus adalimumab (Humira) in the treatment of active psoriatic arthritis.
This is a 52 week trial comparing adalimumab versus secukinumab for the treatment of active psoriatic arthritis. Both treatments are FDA approved for psoriatic arthritis; however this study seeks to determine which drug is superior.
Psoriatic Arthritis
Local doctors are looking for people with Psoriatic Arthritis for clinical research studies of an investigational medication Must be receiving treatment for Psoriatic Arthritis Must be at least 18 years old Psoriatic Arthritis must be present for at least 3 months prior to first visit All patients will receive investigational ...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis
This study will be evaluating the efficacy, tolerability and safety of an oral medication, Tepilamide Fumarate, compared to placebo in the treatment of moderate to severe plaque psoriasis. This is a phase 3, multi-center, randomized, placebo-controlled, double-blind study with a length of 24 weeks. Visits (9 in-office) can include a ...
